BioMarin ($BMRN) rare disease drug missed key Phase 3 goal, raising approval concerns

BioMarin Pharmaceutical reported mixed Phase 3 results for experimental rare disease therapy BMN 401, raising uncertainty around the drug’s regulatory prospects and adding pressure to the company’s efforts to diversify its revenue base.

The therapy succeeded in significantly increasing levels of plasma inorganic pyrophosphate (PPi), a molecule deficient in patients with ENPP1 deficiency, a rare genetic disorder affecting blood vessels and bones. However, the treatment failed to demonstrate improvement on a co-primary endpoint tied to skeletal health, which had been added following discussions with regulators.

BioMarin also said no positive trends were observed across secondary endpoints in the late-stage study involving 27 pediatric patients.

The setback represented a challenge for BioMarin as the company continued reshaping its portfolio under CEO Alexander Hardy. In recent years, the biotech has reduced costs, cut programmes and moved to diversify beyond its leading dwarfism therapy Voxzogo amid growing competitive pressure.

BMN 401 was acquired through BioMarin’s $270 million purchase of Inozyme Pharma and had been viewed as a potential growth opportunity within the company’s rare disease pipeline.

Analysts reacted cautiously to the results, with concerns focusing on the therapy’s regulatory pathway after missing a clinically meaningful endpoint increasingly important to approval decisions.

The disappointing data may increase investor focus on BioMarin’s broader pipeline strategy and future business development efforts as the company looks for new long-term revenue drivers across rare disease markets.